Senolytics: Opening avenues in drug discovery to find novel therapeutics for Parkinson's Disease.

Kakoty, V; Kalarikkal Chandran, S; Gulati, M; Goh, BH; Dua, K; Kumar Singh, S

Senolytics: Opening avenues in drug discovery to find novel therapeutics for Parkinson's Disease.

Kakoty, V Kalarikkal Chandran, S Gulati, M Goh, BH Dua, K

Kumar Singh, S

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Drug Discov Today, 2023, 28, (6), pp. 103582
Issue Date:: 2023-04-05

Closed Access

	Filename	Description	Size
	Senolytics_Parkinsons Disease_1-s2.0-S1359644623000983-main.pdf	Published version	917.11 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Kakoty, V
dc.contributor.author	Kalarikkal Chandran, S
dc.contributor.author	Gulati, M
dc.contributor.author	Goh, BH
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Kumar Singh, S
dc.date.accessioned	2023-04-29T09:19:35Z
dc.date.available	2023-03-30
dc.date.available	2023-04-29T09:19:35Z
dc.date.issued	2023-04-05
dc.identifier.citation	Drug Discov Today, 2023, 28, (6), pp. 103582
dc.identifier.issn	1359-6446
dc.identifier.issn	1878-5832
dc.identifier.uri	http://hdl.handle.net/10453/170137
dc.description.abstract	Aging is one of the major risk factors for most neurodegenerative disorders including Parkinson's disease (PD). More than 10 million people are affected with PD worldwide. One of the predominant factors accountable for progression of PD pathology could be enhanced accumulation of senescent cells in the brain with the progress of age. Recent investigations have highlighted that senescent cells can ignite PD pathology via increased oxidative stress and neuroinflammation. Senolytics are agents that kill senescent cells. This review mainly focuses on understanding the pathological connection between senescence and PD, with emphasis on some of the recent advances made in the area of senolytics and their evolution to potential clinical candidates for future pharmaceuticals against PD.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier
dc.relation.ispartof	Drug Discov Today
dc.relation.isbasedon	10.1016/j.drudis.2023.103582
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0601 Biochemistry and Cell Biology, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Medicinal & Biomolecular Chemistry
dc.title	Senolytics: Opening avenues in drug discovery to find novel therapeutics for Parkinson's Disease.
dc.type	Journal Article
utslib.citation.volume	28
utslib.location.activity	England
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2023-04-29T09:19:34Z
pubs.issue	6
pubs.publication-status	Published online
pubs.volume	28
utslib.citation.issue	6

Abstract:

Aging is one of the major risk factors for most neurodegenerative disorders including Parkinson's disease (PD). More than 10 million people are affected with PD worldwide. One of the predominant factors accountable for progression of PD pathology could be enhanced accumulation of senescent cells in the brain with the progress of age. Recent investigations have highlighted that senescent cells can ignite PD pathology via increased oxidative stress and neuroinflammation. Senolytics are agents that kill senescent cells. This review mainly focuses on understanding the pathological connection between senescence and PD, with emphasis on some of the recent advances made in the area of senolytics and their evolution to potential clinical candidates for future pharmaceuticals against PD.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/170137